A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.

Chigutsa E, Her L, Ma X, Urva S, Schneck K

Clinical pharmacology and therapeutics25 Jun 2025Cited by 2 (Europe PMC)

PMID40556483PMCIDPMC12641085DOI10.1002/cpt.3750PepBankPUB-40556483

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, an exposure-response model showed tirzepatide reduced fat mass about three times as much as fat-free mass.
In plain wordsIn adults with overweight or obesity, a model showed tirzepatide cut fat mass about three times as much as fat-free mass.
Peptide
Tirzepatide
Outcome
DecreaseModelled fat mass reduction versus fat-free mass reduction
Study
n = 2,539
Comparator
Fat-free mass reduction
Outcome group
Body composition · Metabolic and weight
Studied dose
5, 10 or 15 mgAs given in this study (human).
Source sentences
Summary
The exposure-response model revealed that administration of tirzepatide resulted in three times greater reduction of fat mass than that of FFM.
1 context sentence(design, population, supporting numbers)
Summary · context
Monthly body weight measurements were available from 2,539 study participants in a phase 3 clinical trial investigating placebo, 5, 10, or 15 mg of tirzepatide administered once-weekly.
Report a problemFND-4055648301
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, the modelled differential effect of tirzepatide on fat mass and fat-free mass improved body composition over time.
In plain wordsIn adults with overweight or obesity, a model showed body composition improved over time with tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableBody composition improvement over time
Study
n = 2,539
Outcome group
Body composition · Metabolic and weight
Studied dose
5, 10 or 15 mgAs given in this study (human).
Source sentences
Summary
This differential effect resulted in improved body composition over time.
2 context sentences(design, population, supporting numbers)
Summary · context
The exposure-response model revealed that administration of tirzepatide resulted in three times greater reduction of fat mass than that of FFM.
Summary · context
Monthly body weight measurements were available from 2,539 study participants in a phase 3 clinical trial investigating placebo, 5, 10, or 15 mg of tirzepatide administered once-weekly.
Report a problemFND-4055648302
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, the model showed females achieved greater weight reduction than males for the same tirzepatide exposure.
In plain wordsIn adults with overweight or obesity, a model showed women lost more weight than men at the same tirzepatide exposure.
Peptide
Tirzepatide
Outcome
Not applicableSex difference in weight reduction at the same exposure
Study
n = 2,539
Comparator
Males
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mgAs given in this study (human).
Source sentences
Summary
For the same drug exposure, females achieved greater weight reduction than males.
1 context sentence(design, population, supporting numbers)
Summary · context
Monthly body weight measurements were available from 2,539 study participants in a phase 3 clinical trial investigating placebo, 5, 10, or 15 mg of tirzepatide administered once-weekly.
Report a problemFND-4055648303
04HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, the model showed participants with higher baseline weight or BMI had a slower rate of weight reduction with tirzepatide.
In plain wordsIn adults with overweight or obesity, a model showed people with a higher starting weight or BMI lost weight more slowly on tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableBaseline weight or BMI and rate of weight reduction
Study
n = 2,539
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mgAs given in this study (human).
Source sentences
Summary
Study participants with higher baseline weight or body mass index at baseline had a slower rate of weight reduction and were expected to take longer to reach their nadir weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Monthly body weight measurements were available from 2,539 study participants in a phase 3 clinical trial investigating placebo, 5, 10, or 15 mg of tirzepatide administered once-weekly.
Report a problemFND-4055648304

Studies that did not test the peptide alone1

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

05HumanNot a test of Tirzepatide aloneRandomized controlled trialOther
The body composition model agreed well with DXA measurements from a 10% subset of the phase 3 trial participants (a model validation result).
In plain wordsA body composition model agreed well with scan measurements in a 10% subset of trial participants.
Peptide
Tirzepatide
Outcome
Not applicableModel agreement with DXA measurements
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
The model results showed good agreement with available data from a subset (10%) of clinical trial participants who had dual energy x-ray absorptiometry (DXA) measurements.
1 context sentence(design, population, supporting numbers)
Summary · context
Monthly body weight measurements were available from 2,539 study participants in a phase 3 clinical trial investigating placebo, 5, 10, or 15 mg of tirzepatide administered once-weekly.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4055648305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.